Skip to content

Oncotelic Therapeutics, Inc.

OTLC

CIK 0000908259

← back to feed
Revenue (TTM)
$1.74M
Q1 May 2026
Net Income (TTM)
−$3.26M
+5,610.2% YoY Q1 May 2026
EPS Diluted (TTM)
−$0.01
+6,000.0% YoY Q1 May 2026
Gross Margin
—
Q1 May 2026
Operating Margin
-144.3%
Q1 May 2026
Net Margin
-187.4%
Q1 May 2026
Free Cash Flow (TTM)
−$1M
Q1 May 2026
Cash
$409K
Q1 May 2026
Total Debt
$2.72M
Q1 May 2026
Shares Outstanding
444.5M sh
Q1 May 2026

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

No data available for this metric.

Balance Sheet

Cash vs Debt

Recent filings